Deoxyuridine monophosphate reverses resistance to 5FU in 5FU-resistant gastric cancer

被引：0
|
作者：
Mori, R. [1 ]
Tanahashi, T. [1 ]
Okumura, N. [1 ]
Yamaguchi, K. [1 ]
Futamura, M. [1 ]
Yoshida, K. [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Surg Oncol, Gifu, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
209P
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [31] CYTOXAN (CTX) + METHOTREXATE (MTX) + 5FU VS L-PAM + MTX + 5FU IN THE TREATMENT OF ADVANCED BREAST-CANCER
    PLOTKIN, D
    OPFELL, R
    KATTLOVE, H
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 392 - 392
  • [32] Efficacy of 5FU+cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC)
    Ducreux, M
    Douillard, JY
    Pignon, JP
    Seitz, JF
    Bugat, R
    Bosset, JF
    Merrouche, Y
    Raoul, JL
    Ychou, M
    Rougier, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S137 - S137
  • [33] Mechanism for enhanced anti-tumor effects of 5-fluorouracil (5FU) by celecoxib in an advanced colon cancer model: Argiogenesis, or 5FU metabolisms?
    Irie, Takanobu
    Tsujii, Masahiko
    Tsuji, Shingo
    Ishii, Shuji
    Yoshio, Toshiyuki
    Shinzaki, Shinichiro
    Egawa, Satoshi
    Nishida, Tsutomu
    Kakiuchi, Yoshimi
    Yasumaru, Masakazu
    Iijima, Hideki
    Murata, Hiroaki
    Kawano, Sunao
    Hayashi, Norio
    GASTROENTEROLOGY, 2006, 130 (04) : A581 - A581
  • [34] The mismatch repair (MMR) complex hMutSα recognizes 5-fluorouracil (5FU) modified DNA:: a mechanism for 5FU sensitivity
    Tajima, A
    Cabrera, BL
    McMahon, H
    Doctolero, R
    Huang, S
    Carethers, J
    GASTROENTEROLOGY, 2003, 124 (04) : A21 - A21
  • [35] INTRAOCULAR PRESSURE OUTCOME IN PRIMARY 5FU PHACOTRABECULEC- TOMIES COMPARED TO 5FU TRA- BECULECTOMIES
    L.Chang
    M.Thiagarajan
    S.Woodruff
    C.Bentley
    P.T.Khaw
    P.Bloom
    国际眼科杂志, 2003, (01) : 80 - 81
  • [36] The use of palliative protracted infusion 5FU (PVI 5FU) as first line treatment for metastatic oesophageal and gastric cancer patients not suitable for standard cisplatin based combination treatment
    Abdul, Razak A.
    Fox, V
    Coxon, F.
    ANNALS OF ONCOLOGY, 2007, 18 : VII52 - VII52
  • [37] Combined administration of 5-FU with CDHP exert synergistic antitumor effect for 5-FU resistant gastric cancer cells
    Sasaki, E
    Tominaga, K
    Kuwamura, H
    Watanabe, T
    Fujiwara, Y
    Oshitani, N
    Higuchi, K
    Arakawa, T
    Proceedings of the 6th International Gastric Cancer Congress, 2005, : 229 - 231
  • [38] Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin
    Codacci-Pisanelli, G.
    Noordhuis, P.
    van der Wilt, C. L.
    Peters, G. J.
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2008, 27 (6-7): : 733 - 739
  • [39] Hydroxyurea, folinic acid, 5FU bolus and infusion (HLFP regimen) in advanced gastric cancer
    Louvet, C
    deGramont, A
    Beerblock, K
    Mal, F
    Ciribilli, JM
    Varette, C
    Demuyck, B
    Raymond, E
    Gamelin, E
    Colin, P
    Krulik, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 557 - 557
  • [40] Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
    Ryutaro Mori
    Kazuhiro Yoshida
    Toshiyuki Tanahashi
    Kazunori Yawata
    Junko Kato
    Naoki Okumura
    Yasuhiro Tsutani
    Morihito Okada
    Naohide Oue
    Wataru Yasui
    Gastric Cancer, 2013, 16 : 345 - 354
12345